CYTOO is a biotech company developing physiologically relevant cell-based assays compatible with High Content Screening (HCS) by restoring physical cues to cell culture.
The company has developed MyoScreenФ™, the first human skeletal muscle in vitro model compatible with HCS. As part of CYTOO’s engagement into drug discovery, several assays linked to muscle metabolism, contractility, and disorders (Duchenne Muscular Dystrophy, sarcopenia, cachexia) have been developed and are being screened to identify novel active compounds.
CYTOO has also developed EpiScreen™, a stratified skin microepidermis model, enabling high content analysis and high throughput screening for applications in cosmetology and dermatology.